Imperial College London
Alternate

Professor Toby Maher

Faculty of Medicine, National Heart & Lung Institute

Professor of Interstitial Lung Disease
 
 
 
//

Contact

 

+44 (0)20 7594 2151t.maher

 
 
//

Assistant

 

Ms Georgina Moss +44 (0)20 7594 2151

 
//

Location

 

364Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Noth:2021:10.1183/13993003.01518-2020,
author = {Noth, I and Cottin, V and Chaudhuri, N and Corte, TJ and Johannson, KA and Wijsenbeek, M and Jouneau, S and Michael, A and Quaresma, M and Rohr, KB and Russell, A-M and Stowasser, S and Maher, TM and INMARK, trial investigators},
doi = {10.1183/13993003.01518-2020},
journal = {European Respiratory Journal},
pages = {1--10},
title = {Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial},
url = {http://dx.doi.org/10.1183/13993003.01518-2020},
volume = {58},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).Subjects with IPF and preserved forced vital capacity (FVC) were randomised to receive nintedanib or placebo for 12weeks followed by open-label nintedanib for 40weeks. Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Subjects were asked to perform home spirometry at least once a week and ideally daily. Correlations between home- and clinic-measured FVC and rates of change in FVC were assessed using Pearson correlation coefficients.In total, 346 subjects were treated. Mean adherence to weekly home spirometry decreased over time but remained above 75% in every 4-week period. Over 52weeks, mean adherence was 86%. Variability in change from baseline in FVC was greater when measured by home rather than clinic spirometry. Strong correlations were observed between home- and clinic-measured FVC at all time-points (r=0.72 to 0.84), but correlations between home- and clinic-measured rates of change in FVC were weak (r=0.26 for rate of decline in FVC over 52weeks).Home spirometry was a feasible and valid measure of lung function in patients with IPF and preserved FVC, but estimates of the rate of FVC decline obtained using home spirometry were poorly correlated with those based on clinic spirometry.
AU  - Noth,I
AU  - Cottin,V
AU  - Chaudhuri,N
AU  - Corte,TJ
AU  - Johannson,KA
AU  - Wijsenbeek,M
AU  - Jouneau,S
AU  - Michael,A
AU  - Quaresma,M
AU  - Rohr,KB
AU  - Russell,A-M
AU  - Stowasser,S
AU  - Maher,TM
AU  - INMARK,trial investigators
DO  - 10.1183/13993003.01518-2020
EP  - 10
PY  - 2021///
SN  - 0903-1936
SP  - 1
TI  - Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial
T2  - European Respiratory Journal
UR  - http://dx.doi.org/10.1183/13993003.01518-2020
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33419890
UR  - https://erj.ersjournals.com/content/58/1/2001518
UR  - http://hdl.handle.net/10044/1/86224
VL  - 58
ER  -
Download